H N Mishra, Sadanand Shetty, Arun Chopra, Girish B Navasundi, Ashwani Mehta, Dayanand Kumbla, Peeyush Jain, Dibya K Baruah, Amit Singhal, Y S Kumar, K A Sambasivam, Anurag Sharma, Sachin Patil, Gaurav Chaudhary, Y K Singh, P K Deb, M Jawahar, Swapan K Saha, Nilesh Parshottam, Y S Rao, Dilip K Ratnani, Vikrant Vijan, P C Sarma, A Purnanad, Anand Parikh, Arun Mohanty, Biswadev B Majumdar, Dipak R Das, Harshit Gupta, Keshav Kale, Krutik Kulkarni, Miraj Modal, Nikhil Motiramani, Nimit Shah, Nishad Chitnis, Pankaj Goyal, Ragavendra, Srikanth Bodepudi, Thiyagarajan, Tirthankar Roy, U P Singh, Uttam K Saha, Vinod Kumar, Vithal D Baghi, Vivudh P Singh, Aditya Rattan, Anil Gomber, Ankur Dasgupta, Biswa R Jena, D K Garg, Dipankar Deb, Farah Ingale, Ganesh Seth, Gaurav Tripathi, K Deelip Kumar, Manoj Chitale, N Kumaralingam, Nandakumaran, P R Ramulu, Piyush Dabhi, S Pradeep, Rajeev Mehra, Sekhar Chakraborty, Sunil Dube, Sunil Kohli, T K Batabyal, T V Narayan Rao, V H Kriplani, Heena Bhojwani, Bhakti Sawant, Priyank Shah, Sanjay Jain
{"title":"Management of Hypertension and Associated Comorbidities: An Expert Consensus Statement from India.","authors":"H N Mishra, Sadanand Shetty, Arun Chopra, Girish B Navasundi, Ashwani Mehta, Dayanand Kumbla, Peeyush Jain, Dibya K Baruah, Amit Singhal, Y S Kumar, K A Sambasivam, Anurag Sharma, Sachin Patil, Gaurav Chaudhary, Y K Singh, P K Deb, M Jawahar, Swapan K Saha, Nilesh Parshottam, Y S Rao, Dilip K Ratnani, Vikrant Vijan, P C Sarma, A Purnanad, Anand Parikh, Arun Mohanty, Biswadev B Majumdar, Dipak R Das, Harshit Gupta, Keshav Kale, Krutik Kulkarni, Miraj Modal, Nikhil Motiramani, Nimit Shah, Nishad Chitnis, Pankaj Goyal, Ragavendra, Srikanth Bodepudi, Thiyagarajan, Tirthankar Roy, U P Singh, Uttam K Saha, Vinod Kumar, Vithal D Baghi, Vivudh P Singh, Aditya Rattan, Anil Gomber, Ankur Dasgupta, Biswa R Jena, D K Garg, Dipankar Deb, Farah Ingale, Ganesh Seth, Gaurav Tripathi, K Deelip Kumar, Manoj Chitale, N Kumaralingam, Nandakumaran, P R Ramulu, Piyush Dabhi, S Pradeep, Rajeev Mehra, Sekhar Chakraborty, Sunil Dube, Sunil Kohli, T K Batabyal, T V Narayan Rao, V H Kriplani, Heena Bhojwani, Bhakti Sawant, Priyank Shah, Sanjay Jain","doi":"10.59556/japi.73.1094","DOIUrl":null,"url":null,"abstract":"<p><p>Hypertension is a leading global health concern that significantly contributes to cardiovascular (CV) and renal diseases. In India, its prevalence is rising, often coexisting with comorbidities such as type 2 diabetes mellitus (T2DM), chronic kidney disease (CKD), coronary artery disease (CAD), and metabolic syndrome (MetS). Effective hypertension management in these populations is challenging due to variations in blood pressure (BP) targets, the need for combination therapy, and the complexity of treating associated conditions such as albuminuria, nephropathy, CKD, CAD, and acute coronary syndromes (ACS). Despite advancements in treatment options, inconsistencies in clinical practice highlight the need for standardized, evidence-based recommendations. This expert consensus aims to address these gaps by guiding BP targets, optimal antihypertensive strategies, and individualized treatment approaches for high-risk patients. Key considerations include the role of renin-angiotensin-aldosterone system blockers, calcium channel blockers (CCBs), beta-blockers (BBs), sodium-glucose cotransporter-2 inhibitors, and combination therapies in improving CV and renal outcomes. By establishing clear, consensus-driven recommendations, this statement seeks to enhance hypertension management, promote early intervention, and improve patient outcomes in India.</p>","PeriodicalId":22693,"journal":{"name":"The Journal of the Association of Physicians of India","volume":"73 9","pages":"e48-e59"},"PeriodicalIF":0.0000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of the Association of Physicians of India","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.59556/japi.73.1094","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Hypertension is a leading global health concern that significantly contributes to cardiovascular (CV) and renal diseases. In India, its prevalence is rising, often coexisting with comorbidities such as type 2 diabetes mellitus (T2DM), chronic kidney disease (CKD), coronary artery disease (CAD), and metabolic syndrome (MetS). Effective hypertension management in these populations is challenging due to variations in blood pressure (BP) targets, the need for combination therapy, and the complexity of treating associated conditions such as albuminuria, nephropathy, CKD, CAD, and acute coronary syndromes (ACS). Despite advancements in treatment options, inconsistencies in clinical practice highlight the need for standardized, evidence-based recommendations. This expert consensus aims to address these gaps by guiding BP targets, optimal antihypertensive strategies, and individualized treatment approaches for high-risk patients. Key considerations include the role of renin-angiotensin-aldosterone system blockers, calcium channel blockers (CCBs), beta-blockers (BBs), sodium-glucose cotransporter-2 inhibitors, and combination therapies in improving CV and renal outcomes. By establishing clear, consensus-driven recommendations, this statement seeks to enhance hypertension management, promote early intervention, and improve patient outcomes in India.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
